Trial Profile
A Phase I/II, Single-Masked, Multicenter Study of the Safety, Tolerability, and Efficacy of Multiple-Dose Intravitreal Injections of rhuFab V2 in Combination With Verteporfin (Visudyne(R)) Photodynamic Therapy in Subjects With Neovascular Age Related Macular Degeneration
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 23 Oct 2014
Price :
$35
*
At a glance
- Drugs Ranibizumab (Primary) ; Verteporfin
- Indications Age-related macular degeneration; Choroidal neovascularisation; Wet age-related macular degeneration
- Focus Adverse reactions; Therapeutic Use
- Sponsors Genentech
- 23 Oct 2014 New trial record